Juniper Pharma Services (JPS), a contract development and manufacturing organisation (CDMO) specialising in the development of challenging small molecules, will be attending the Advancing Drug Development Forum (ADDF) - Making the Impossible, Possible, on 14 June at the San Francisco Wine School, California.
JPS will be joining key opinion leaders at the inaugural West Coast ADDF event, which brings together a high calibre network of industry leaders from across pharma and biotechnology.
The focused group of executive leaders, senior directors and consultants will come together to discuss the importance of innovation in small molecule drug formulation and manufacturing methods.
The forum will explore better ways to face the many new challenges that still lie ahead and search for better solutions employing entrepreneurial and novel technologies to develop important complex compounds, to treat unmet medical conditions.
Don Dickison, VP of Business Development at Juniper Pharma Services said: “We are incredibly excited to connect with industry thought leaders at ADDF and to explore the challenges faced in small molecule drug development. Through the exchange of ideas and experiences we hope to continue to find pathways to successful therapeutics to address unmet medical needs.”
The event will feature a range of panel discussions tackling current and provocative topics and keynote presentations from key industry thought leaders.
The prestigious line-up of speakers includes Dr Alok Tayi, CEO, TetraScience, who will present the opening Keynote on 'The Digital Biotech', Lara Park-Menning, Nucleo Life Sciences, talking about 'Giving Failed Drugs A Fresh Start & A New Direction', Dr Simon McGurk, Executive Director, TESARO, who will discuss 'Success in the Virtual Pharma World - The Impact of Your CDMO' and Kevin J. Bittorf, VP CMC and BD, Trek Therapeutics on “The Value IOT Brings Developing a Quality Product”.